Introduction
Introduction of the 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors (statins) revolutionized the treatment of hypercholesterolemia, and numerous clinical trials have shown that statins can significantly reduce the incidence of coronary artery disease (CAD) in both primary and secondary prevention settings 1, 2) . It has also been demonstrated that intensive lipid-lowering therapy with statins sig-level compared with statin monotherapy [9] [10] [11] . Increased levels of remnant-like particle (RLP)-C 12) , lipoprotein (a) [Lp(a)] 13) , and oxidized LDL (Ox-LDL) 14) have been recognized as risk factors for CAD. RLP-C 15, 16) and Ox-LDL 16) are both decreased by statin therapy; however, the effect of statin therapy on Lp(a) is controversial, although some studies have demonstrated that statins can reduce the Lp(a) level 17) . It also remains unclear whether ezetimibe can reduce the levels of RLP-C, Lp(a), and Ox-LDL. In the present study, we prospectively evaluated the influence of ezetimibe on RLP-C, Lp(a), and Ox-LDL levels in patients with dyslipidemia.
Materials and Methods

Subjects
Fifty patients with dyslipidemia (male/female 22/28, mean age 70 9 years) who did not achieve target lipid levels according to Japan Atherosclerosis Society guidelines 18) when treated with diet, exercise, and/or statin therapy were administered 10 mg/day ezetimibe. Ezetimibe was added to statin therapy in 25 patients and the other 25 patients were treated with ezetimibe alone. Patients were excluded from the study for the following reasons: (1) treatment with non-statin lipid-lowering drugs (fibrates, nicotinic acid, colestyramine, and probucol), (2) severe liver dysfunction, (3) dyslipidemia associated with hypothyroidism, nephrotic syndrome, gallbladder obstruction, biliary disease, pancreatitis, or immunologic abnormalities, such as collagen diseases, (4) alcoholism or heavy alcohol intake, (5) dyslipidemia induced by steroids or other drugs, (6) diabetic patients who were receiving insulin or who were poorly controlled [hemoglobin A1c (HbA1c) 8.0%], and (7) any other reason for which the patient was considered inappropriate for this study by the attending physician.
At baseline and 12 weeks after treatment with ezetimibe, we measured the levels of RLP-C, Lp(a), Ox-LDL, and high-sensitivity C-reactive protein (hs-CRP). In patients with previously diagnosed diabetes mellitus (DM) or impaired glucose tolerance, HbA1c was also measured. Anti-diabetic drugs were not changed during the study period. Written informed consent was obtained from all patients, and the Ethics Committee of Yokohama Sakae Kyosai Hospital approved the study protocol.
Laboratory Determination
Blood samples were obtained after an overnight fast. Serum levels of total cholesterol (TC), LDL-C, high-density lipoprotein (HDL)-C, and TG were measured by standard enzymatic methods. Serum levels of apolipoproteins, RLP-C, Lp(a), Ox-LDL, and hs-CRP were measured at a central laboratory (SRL Inc., Tokyo, Japan). The serum level of RLP-C was measured by an immune-separation technique 19) , Lp(a) was measured by a latex agglutination assay 20) , and Ox-LDL was measured by an enzyme immunoassay 21) , as previously described.
Statistical Analysis
Statistical analyses were performed with Statview 5.0 software (SAS Institute, Cary, NC, USA). Results are expressed as the mean SD or median (range). Differences in continuous variables between groups were compared by the unpaired t -test when the variable showed a normal distribution, or by the MannWhitney U -test when it did not. Differences in continuous variables within each group were compared by the paired t -test when the variable showed a normal distribution, or by the Wilcoxon signed-ranks test when it did not. The significance of differences in percentages was analyzed by the chi-square test. Univariate linear regression analyses were performed to assess the relation between the mean change of RLP-C and various other parameters. Stepwise regression analysis was also performed to identify factors that were independently associated with the reduction of RLP-C levels. A significant difference was defined as p 0.05.
Results
The baseline characteristics of the patients are shown in Table 1 . There were 22 men and 28 women with a mean age of 70 9 years. The mean baseline levels of TC, LDL-C, HDL-C, TG, RLP-C, and Ox-LDL were 229 39 mg/dL, 151 34 mg/dL, 61 15 mg/dL, 162 82 mg/dL, 6.8 4.0 mg/dL, and 10.2 6.8 U/mL, respectively. The median baseline level of Lp(a) was 14 mg/dL. TC and LDL-C levels were significantly lower in the ezetimibe+statin group. Patients in this group were already being treated with statins because of a history of CAD and/or DM.
The effects of ezetimibe administration on lipid parameters, hs-CRP, FPG, and HbA1c are shown in Table 2 . The levels of TC, LDL-C, TG, non-HDL-C, and apolipoprotein (apo) B respectively showed a significant decrease from 229 39 to 191 37 mg/dL ( 16%, p 0.0001), from 151 34 to 118 33 mg/dL ( 22%, p 0.0001), from 162 82 to 135 55 mg/ dL ( 7%, p 0.01), from 168 36 to 130 34 mg/dL ( 22%, p 0.0001), and from 116 22 to 94 21 mg/dL ( 18%, p 0.0001) after 12 weeks of treatment with ezetimibe. HDL-C showed no significant change, whereas the LDL-C/HDL-C ratio decreased significantly from 2.6 0.8 to 2.0 0.8 (p 0.0001). The administration of ezetimibe did not significantly affect the ratio of LDL-C to apo B. RLP-C decreased significantly from 6.8 4.0 to 4.8 2.5 mg/dL ( 21%, p 0.0001), but Ox-LDL was not decreased by ezeti- mibe therapy. Fasting plasma glucose (FPG) and HbA1c, respectively, showed a significant decrease from 113 26 to 108 22 mg/dL (p 0.05) and from 6.3 0.6 to 6.1 0.7% (p 0.01). Compared with the baseline, the median level of hs-CRP was reduced by ezetimibe therapy from 0.6 to 0.4 mg/L ( 33%, p 0.05) ( Table 2) . According to univariate analyses, the mean change of RLP-C was positively correlated with the mean change of TG (r 0.784, p 0.0001) or apo E (r 0.553, p 0.0001) ( Table 3) . Stepwise regression analysis showed that the mean change of TG was a significant independent predictor of the reduction of RLP-C levels (p 0.0001) ( Table 4) . No adverse effects were observed and the level of alkaline phosphatase (ALP) showed a significant decrease due to treatment with ezetimibe ( Table 5) .
Discussion
This is the first study to examine the effects of ezetimibe on RLP-C, Lp(a), and Ox-LDL in patients with dyslipidemia. Our results suggested that ezeti- TC, total cholesterol; LDL-C, low-density lipoprotein cholesterol; TG, triglycerides; HDL-C, high-density lipoprotein cholesterol; apo B, apolipoprotein B; RLP-C, remnant-like particle cholesterol. : All patients, : Ezetimibe group, : Ezetimibe+statin group. Tables 1 and 2. mibe therapy was useful for reducing RLP-C levels. Although Ox-LDL was not decreased, Lp(a) was reduced by ezetimibe monotherapy. The percent change of TC, LDL-C, TG, non-HDL-C, apo B, and RLP-C after 12 weeks of treatment with ezetimibe was 16%, 22%, 7%, 22%, 18%, and 21%, respectively. These percent changes tended to be larger in the ezetimibe statin group, but the differences were not statistically significant. According to previous reports, ezetimibe monotherapy achievesd an approximately 17 − 18% reduction of LDL-C 9, 22) . When added to statin, ezetimibe producesd a significant 21 − 23% additional mean percent reduction of LDL-C compared with statin monotherapy 10, 11) . Thus, combining ezetimibe with a statin leads to incremental reduction of LDL-C.
In the present study, the RLP-C level was also decreased by ezetimibe therapy and the mean change of RLP-C was positively correlated with the mean change of TG. What is the mechanism through which RLP-C is reduced by ezetimibe therapy ? In order to maintain stable cholesterol homeostasis, enterocytes regulate the uptake and secretion of cholesterol.
NPC1L1 protein is involved in the direct uptake of cholesterol from the intestinal lumen. Since ezetimibe inhibits this protein function, it seems likely that ezetimibe therapy would lead to qualitative or quantitative changes of apo B-48-containing particles. Less cholesterol would be transported in chylomicrons, implying a reduction of cholesterol reaching the liver in chylomicron remnants 8, 23) . This decrease of chylomicrons is the first reason for the reduction of RLP-C with ezetimibe therapy. In addition, a decrease of hepatic cholesterol 23, 24) and an increase of hepatic LDL receptor (LDLR) expression 24) has been reported in ezetimibetreated mice. Temel et al. studied transgenic mice with overexpression of human NPC1L1 by hepatocytes, and found a decrease of biliary cholesterol in association with a 30 − 60% increase of plasma cholesterol 25) . Since these changes were blocked by treatment with ezetimibe, ezetimibe may reduce plasma cholesterol by inhibiting NPC1L1 activity in both the intestine and liver 25) . This reduction of hepatic cholesterol is the second reason for the decrease of RLP-C with ezetimibe therapy. It seems possible that these effects of ezetimibe could alleviate hepatic steatosis and lead to the improvement of insulin resistance 26) . Indeed, the present study showed that FPG, HbA1c, and ALP levels were decreased significantly by ezetimibe therapy. Furthermore, aspartate aminotransferase (AST), alanine aminotransferase (ALT), and -glutamyl trans- Stepwise regression analysis was performed using 7 variables: TC, LDL-C, HDL-C, TG, Apo AI, Apo B, and Apo E. peptidase ( -GTP) levels were decreased by ezetimibe therapy in some patients (data not shown). This improvement of insulin resistance is the third reason for the decrease of RLP-C with ezetimibe therapy. There are only limited data on the effects of ezetimibe on the lipoproteins profile. Kalogirou et al. reported that ezetimibe monotherapy significantly reduced the concentrations of all LDL subfractions 27) . Furthermore, the reduction of small dense (sd)-LDL subfractions was greater than that of large buoyant fractions. Although ezetimibe administration induced a shift towards larger LDL particles, the ratio of LDL-C to apo B (that has been used as a marker of sd-LDL) was not significantly affected 27) . Thus, some studies demonstrated that the ratio of LDL-C to apo B was not an accurate marker of the distribution of LDL subfractions 27, 28) . Indeed, the administration of ezetimibe did not significantly affect the ratio of LDL-C to apo B in the present study.
There is strong evidence that oxidized lipoproteins, particularly Ox-LDL, play a key role in the pathogenesis of atherosclerosis 14) , but the mechanisms by which lipoproteins are oxidized are still not well understood. Lipoprotein-associated phospholipase A2 (Lp-PLA2) degrades the short-chain sn-2-analogs of phosphatidylcholine generated upon Ox-LDL 29) . A higher Lp-PLA2 level was strongly associated with an increased risk of CAD 30) . It has been reported that statins decrease the Lp-PLA2 level 31) , reduce the susceptibility of LDL to oxidation 32) , and lead to the reduction of Ox-LDL 16) . The reasons why Ox-LDL could not be decreased by ezetimibe therapy are unclear. We speculate that ezetimibe could not influence the Lp-PLA2 level and oxidization of LDL during circulation, though it inhibits the incorporation of dietary oxidized cholesterol into lipoproteins 33) . Further studies are necessary to clarify whether ezetimibe affects the level of Ox-LDL.
Lp(a) is a cholesteryl ester-and apo B-containing particle that differs from LDL due to the presence of a glycoprotein termed apo(a), which is homologous with plasminogen. No specific Lp(a)-lowering agents have been discovered. The effect of statins on Lp(a) is controversial, although some studies have demonstrated that statins can reduce the Lp(a) level 17) . In the present study, the median level of Lp(a) was decreased by 29% due to ezetimibe monotherapy. Though the Lp(a) level is mainly determined by genetic variation of the apo(a) gene 34) , hypercholesterolemia is associated with a high Lp(a) level 35) . The mechanism through which Lp(a) is decreased by ezetimibe remains unclear. The reduction of the Lp(a) level may be partly explained by an anti-inflammatory effect of ezetimibe, because the Lp(a) level is correlated with those of acute-phase reactants in hypercholesterolemic patients 36) . It has been reported that hs-CRP predicts morbidity and mortality from CAD 37) . Statins reduce the hs-CRP level in a manner largely independent of the LDL-C level 38) and statin plus ezetimibe therapy reduces the hs-CRP level more effectively than statin monotherapy 10) . In the present study, hs-CRP was decreased significantly by ezetimibe therapy. Previous data suggest that ezetimibe reduces hs-CRP when given in combination with other agents only 9) ; however, recent studies have reported that ezetimibe monotherapy also has an anti-inflammatory effect 39, 40) . There was no correlation between the reduction of hs-CRP and LDL-C in the present study (data not shown), which was also reported previously 39) . This effect of ezetimibe is pleiotropic, because it is not absorbed into the circulation but acts locally by inhibiting cholesterol absorption from the small intestine. Further studies are necessary to clarify the mechanisms of ezetimibe for reducing the hs-CRP level.
In conclusions, ezetimibe therapy decreased the levels of TC, LDL-C, TG, and RLP-C. Ezetimibe shows an anti-atherogenic effect by not only reducing the LDL-C level, but also the RLP-C level. Ezetimibe could be a potential therapeutic option for decreasing the Lp(a) level.
Study Limitations
There are some limitations with regard to the interpretation of our results. Because there were only 50 patients in the study, the small sample size meant that analysis of the response of RLP-C, Lp(a), and Ox-LDL to ezetimibe therapy was limited. Furthermore, apo B-48 and apo B-100 were not measured separately in the present study. 
